Cargando…

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Conventional Therapy at Different Periods: A Meta-Analysis of Randomized Controlled Trials

AIMS: To assess the safety of ertugliflozin in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with conventional therapy at different periods. METHODS: We searched PubMed, Embase, and The Cochrane Library from inception to September 23, 2020. A total of six studies involving 41...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Jing, Xiong, Shuyuan, Ding, Shenglan, Cheng, Qingfeng, Liu, Zhiping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7831274/ https://www.ncbi.nlm.nih.gov/pubmed/33532502 http://dx.doi.org/10.1155/2020/9704659

Ejemplares similares

Efficacy and Safety of Ertugliflozin in Patients With Diabetes Mellitus Inadequately Controlled by Sulfonylurea Monotherapy: a Substudy of VERTIS CV
por: Strojek, Krzysztof, et al.
Publicado: (2021)

Safety and efficacy of ertugliflozin in Asian patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: VERTIS Asia
por: Ji, Linong, et al.
Publicado: (2019)

Ertugliflozin Compared with Glimepiride in Patients with Type 2 Diabetes Mellitus Inadequately Controlled on Metformin: The VERTIS SU Randomized Study
por: Hollander, Priscilla, et al.
Publicado: (2017)

Efficacy and safety of the addition of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sitagliptin: The VERTIS SITA2 placebo‐controlled randomized study
por: Dagogo‐Jack, Samuel, et al.
Publicado: (2017)

Long‐term efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin monotherapy: 104‐week VERTIS MET trial
por: Gallo, Silvina, et al.
Publicado: (2019)

Efficacy and Safety of Ertugliflozin in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea: A Sub-Study of VERTIS CV
por: Budoff, Matthew J., et al.
Publicado: (2021)

Safety of Ertugliflozin in Patients with Type 2 Diabetes Mellitus: Pooled Analysis of Seven Phase 3 Randomized Controlled Trials
por: Patel, Shrita, et al.
Publicado: (2020)

Role of Ertugliflozin in the Management of Diabetes Mellitus
por: Totade, Manisha, et al.
Publicado: (2022)

Long‐term efficacy and safety of ertugliflozin monotherapy in patients with inadequately controlled T2DM despite diet and exercise: VERTIS MONO extension study
por: Aronson, Ronnie, et al.
Publicado: (2018)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Effectiveness and safety of ertugliflozin for type 2 diabetes: A meta‐analysis of data from randomized controlled trials
por: Zhang, Fudan, et al.
Publicado: (2021)

Ertugliflozin in the treatment of type 2 diabetes mellitus
por: Marrs, Joel C, et al.
Publicado: (2020)

Efficacy and Safety of Ertugliflozin in Patients with Overweight and Obesity with Type 2 Diabetes Mellitus
por: Heymsfield, Steven B., et al.
Publicado: (2020)

Effect of Food on the Pharmacokinetics of Ertugliflozin and Its Fixed‐Dose Combinations Ertugliflozin/Sitagliptin and Ertugliflozin/Metformin
por: Sahasrabudhe, Vaishali, et al.
Publicado: (2018)

Overview of Ertugliflozin
por: Nguyen, Vivianne K., et al.
Publicado: (2019)

Efficacy and safety of ertugliflozin in East/Southeast Asian patients with type 2 diabetes mellitus
por: Liu, Jie, et al.
Publicado: (2020)

Efficacy and Safety of Ertugliflozin in Type 2 Diabetes: A Systematic Review and Meta-Analysis
por: Liu, Li, et al.
Publicado: (2022)

Effect of ertugliflozin on blood pressure in patients with type 2 diabetes mellitus: a post hoc pooled analysis of randomized controlled trials
por: Liu, Jie, et al.
Publicado: (2019)

The Mediating Effects of Diabetes Distress, Anxiety, and Cognitive Fusion on the Association Between Neuroticism and Fear of Hypoglycemia in Patients With Type 2 Diabetes
por: Huang, Jing, et al.
Publicado: (2021)

Medication Adherence and Associated Factors in Patients With Type 2 Diabetes: A Structural Equation Model
por: Huang, Jing, et al.
Publicado: (2021)

Ertugliflozin for type 2 diabetes [Correction]
Publicado: (2019)

The Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Subjects With Type 2 Diabetes Mellitus
por: Sahasrabudhe, V., et al.
Publicado: (2017)

Population Pharmacokinetic Model for Ertugliflozin in Healthy Subjects and Patients With Type 2 Diabetes Mellitus
por: Fediuk, Daryl J., et al.
Publicado: (2020)

Fear of hypoglycemia and associated factors in hospitalized patients with type 2 diabetes: a cross‑sectional study
por: Huang, Jing, et al.
Publicado: (2022)

Ertugliflozin in Patients with Stage 3 Chronic Kidney Disease and Type 2 Diabetes Mellitus: The VERTIS RENAL Randomized Study
por: Grunberger, George, et al.
Publicado: (2017)

Efficacy and safety of baricitinib for active rheumatoid arthritis in patients with an inadequate response to conventional synthetic or biological disease-modifying anti-rheumatic drugs: A meta-analysis of randomized controlled trials
por: Wu, Zhi-Peng, et al.
Publicado: (2018)

Efficacy and Safety of Teneligliptin in Indian Patients with Inadequately Controlled Type 2 Diabetes Mellitus: A Randomized, Double-blind Study
por: Agarwal, Piyush, et al.
Publicado: (2018)

Effect of ertugliflozin on renal function and cardiovascular outcomes in patients with type 2 diabetes mellitus: A systematic review and meta-analysis
por: Cheng, Qian, et al.
Publicado: (2023)

Efficacy and safety of ipragliflozin as an add‐on therapy to sitagliptin and metformin in Korean patients with inadequately controlled type 2 diabetes mellitus: A randomized controlled trial
por: Han, Kyung‐Ah, et al.
Publicado: (2018)

Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy
por: Lingvay, Ildiko, et al.
Publicado: (2021)

Novel Application of the Two‐Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin
por: Raje, Sangeeta, et al.
Publicado: (2018)

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
por: Stenlöf, K, et al.
Publicado: (2013)

Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin
por: Rodbard, H. W., et al.
Publicado: (2016)

Bioequivalence of Metformin in Ertugliflozin/Metformin Fixed‐Dose Combination Tablets to Canadian‐Sourced Metformin Coadministered With Ertugliflozin Under Fasted and Fed States
por: Dawra, Vikas Kumar, et al.
Publicado: (2020)

A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma
por: Harris, Jeffrey M., et al.
Publicado: (2016)

Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitus
por: Segar, Matthew W., et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Ertugliflozin in Healthy Japanese and Western Subjects
por: Li, Yinhua, et al.
Publicado: (2021)

Population Pharmacokinetic Analyses of Ertugliflozin in Select Ethnic Populations
por: Fediuk, Daryl J., et al.
Publicado: (2021)

Efficacy and safety of vildagliptin in patients with type 2 diabetes mellitus inadequately controlled with dual combination of metformin and sulphonylurea
por: Lukashevich, V, et al.
Publicado: (2014)

Efficacy and safety of sodium-glucose cotransporter-2 inhibitors in type 2 diabetes mellitus with inadequate glycemic control on metformin: a meta-analysis
por: Jingfan, Zhang, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_5s5p5impfo2jiq0o4r4gcf1ek9